J&J Strikes $2.2 Billion Deal for Eye-Disease Biotech Ollin
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Johnson & Johnson said Nov. 16 it will buy Ollin Biosciences for $2.2 billion upfront, with up to about…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
5 confirmed facts and 3 sources behind this story.